These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19247406)

  • 61. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program.
    Brawer MK
    BJU Int; 2003 Apr; 91(6):465-6. PubMed ID: 12656893
    [No Abstract]   [Full Text] [Related]  

  • 62. Duration of testosterone suppression and the risk of death from prostate cancer in men treated with radiation and 6 months of hormone therapy.
    Palma D; Pickles T
    Cancer; 2008 May; 112(10):2322-3; author reply 2323. PubMed ID: 18327816
    [No Abstract]   [Full Text] [Related]  

  • 63. Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer.
    Nadal R; McMahan ZH; Antonarakis ES
    Clin Genitourin Cancer; 2013 Dec; 11(4):e15-23. PubMed ID: 23820064
    [No Abstract]   [Full Text] [Related]  

  • 64. Cushing syndrome associated with prostatic tumor adrenocorticotropic hormone (ACTH) expression after maximal androgen blockade therapy.
    Kataoka K; Akasaka Y; Nakajima K; Nagao K; Hara H; Miura K; Ishii N
    Int J Urol; 2007 May; 14(5):436-9. PubMed ID: 17511728
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bicalutamide Monotherapy With Radiation Therapy for Localized Prostate Cancer: A Non-Evidence-Based Alternative.
    Jia AY; Spratt DE
    Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):316-319. PubMed ID: 35569476
    [No Abstract]   [Full Text] [Related]  

  • 66. Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment.
    Palmberg C; Kylmala T; Tammela T
    Br J Urol; 1997 May; 79(5):808-9. PubMed ID: 9158528
    [No Abstract]   [Full Text] [Related]  

  • 67. Androgen receptor-positive salivary duct carcinoma: a disease entity with promising new treatment options.
    Jaspers HC; Verbist BM; Schoffelen R; Mattijssen V; Slootweg PJ; van der Graaf WT; van Herpen CM
    J Clin Oncol; 2011 Jun; 29(16):e473-6. PubMed ID: 21422415
    [No Abstract]   [Full Text] [Related]  

  • 68. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [New hormonal treatments of metastatic prostatic cancer. Review of the literature].
    Dubost JJ; Sauvezie B; Ristori JM; Thevenet JP; Rampon S
    Rev Rhum Mal Osteoartic; 1985 Oct; 52(10):577-85. PubMed ID: 3909364
    [No Abstract]   [Full Text] [Related]  

  • 70. Immediate or deferred hormonal therapy?
    Newling DW
    Scand J Urol Nephrol Suppl; 2003; (212):16-9. PubMed ID: 12841322
    [No Abstract]   [Full Text] [Related]  

  • 71. [Early prostate cancer 2005. New 2005 data].
    Fourcade RO
    Ann Urol (Paris); 2006 Dec; 40 Suppl 2():S44-8. PubMed ID: 17361920
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer.
    Dockery F; Bulpitt CJ; Agarwal S; Vernon C; Rajkumar C
    J Androl; 2009; 30(4):410-5. PubMed ID: 19168445
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Androgen deprivation therapy regulation of beta1C integrin expression in prostate cancer.
    Fuzio P; Lucarelli G; Perlino E; Battaglia M; Bettocchi C; Selvaggi FP; Ditonno P
    Oncol Rep; 2009 Aug; 22(2):327-35. PubMed ID: 19578773
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Prostate small cell carcinoma: report of two cases that differed in treatment responsiveness].
    Yoshida T; Nishimura K; Uemura M; Nakagawa K; Harada Y; Kanno N; Miyoshi S; Kawano K
    Hinyokika Kiyo; 2006 Nov; 52(11):891-4. PubMed ID: 17176877
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An unusual case of "sterile" abscess within low-grade meningioma during anti androgenic therapy and LH-releasing hormone agonist treatment for prostate cancer.
    Fabbri VP; Asioli S; Palandri G
    Clin Neurol Neurosurg; 2020 Sep; 196():105993. PubMed ID: 32563976
    [No Abstract]   [Full Text] [Related]  

  • 76. The clinical rationale for immediate androgen deprivation without estrogen deprivation.
    Pitts WR
    Clin Prostate Cancer; 2003 Sep; 2(2):127-8. PubMed ID: 15040875
    [No Abstract]   [Full Text] [Related]  

  • 77. Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex.
    Tsukamoto S; Akaza H; Imada S; Koiso K; Shirai T; Ideyama Y; Kudo M
    J Natl Cancer Inst; 1995 Jun; 87(11):842-3. PubMed ID: 7791234
    [No Abstract]   [Full Text] [Related]  

  • 78. Sense and Sensibility.
    Schattner A
    Am J Med; 2021 Dec; 134(12):1570-1571. PubMed ID: 34214460
    [No Abstract]   [Full Text] [Related]  

  • 79. Estimated potency of Casodex: a problematic design.
    Labrie F; Simard J; Singh SM; Candas B
    Urology; 1997 Aug; 50(2):309-13. PubMed ID: 9255312
    [No Abstract]   [Full Text] [Related]  

  • 80. The role of tamoxifen in reducing bicalutamide-induced gynaecomastia and breast pain.
    Nuttall MC; Harris JP; Dawkins GP
    BJU Int; 2007 Feb; 99(2):243-4. PubMed ID: 17313420
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.